Current recommendations for the treatment of osteoarthritis

Cover Page

Cite item

Full Text

Abstract

The article presents the current national and international guidelines on the management of patients with osteoarthritis. Given the high multimorbid patients with osteoarthritis, presented data on the prevention of complications of drug therapy and worsening current comorbidities. Showing analgesic and anti-inflammatory capabilities symptom-modifying slow-acting medications (symptomatic slow-acting drug for osteoarthritis - SYSADOA) in the treatment of osteoarthritis. The data of domestic and foreign authors on the effectiveness of the combined preparations of SYSADOA group.

About the authors

N. V Chichasova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: kafedrarheum@yandex.ru
д-р мед. наук, проф. каф. ревматологии ИПО ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Bijlsma J.W, Berenbaum F, Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377: 2115-26
  2. Pereira D, Peleteiro D, Araujo J et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartilage 2011; 19: 1279-85.
  3. Галушко Е.А., Большакова Т.В., Виноградова И.Б. и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно - практ. ревматология. 2009; 1: 11-7.
  4. World Health Statistics 2012. Geneva: World Health Organization.
  5. Global, regional, and national incidence, prevalence, and year lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013; a systematic analysis for the Global burden of disease Study. 2013 Global Burden of Disease Study. 2013 Collaborators//www.thelancet.com. Published online June 8, 2015.
  6. Hootman J.M, Helmick C.G, Golightly Y.M. Trends in prevalence of knee pain among US adults, National Health Interview Survey, 2002-2010. Arthr Rheum 2015, 67 (S10): Abstract Suppl. 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 3269.
  7. Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача - терапевта. РМЖ. 2008; 16 (7): 33-7.
  8. Van Dijk G.V, Veenhof C, Schelleviset S et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008; 9: 95.
  9. Mc Alindon T.E, Bannuru R.R, Sullivan M.C et al. OARSI Guidelines for the non - surgical management of knee osteoarthritis. Ostearthr Cartilage 2014; 22: 363-88.
  10. Pelletier J.P, Martel-Pelletier J, Howell D.S. Etiopathogenesis of osteoarthritis. In: Koopman W.J, Ed. Arthritis and Allied Conditions. A Textbook of Rheumatology 13th edn. Baltimore: Williams & Wilkins, 1969; 1984; 1997.
  11. Haseb A, Haggi T.M. Immunopathogenesis of osteoarthritis NIH. Clin Immunol 2013; 146: 185-96.
  12. Osteoarthritis. Clinical and Experimental aspects. Ed. J.-E.Reginster, J.-P.Pelletier, Y.Henrotin. Springer, 1999.
  13. Benito M.J, Veale D.J, Fitz-Gerald O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-7.
  14. Mackenzie I.S, Rutherford D, Mac Donald T.M. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthr Res Ther 2008: 10 (Suppl. 2): 3.
  15. Murphy G, Lee M.H. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 2005; 64: iv44-iv47.
  16. Andersen T.L, del Carmen Ovejero M, Kirkegaard T et al. A scrutinu of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by over cells. Bone 2004; 35: 1107-19.
  17. Алексеева Л.И., Насонов Е.Л. Национальные рекомендации по ведению больных ОА. Официальный сайт ФГБУН «Научно - исследовательский институт ревматологии им. В.А.Насоновой» rheumatology.ru
  18. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике. М.: ИМА-ПРЕСС, 2015.
  19. Helin-Salmivaara A et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case - control study in a general population. Scand J Gastroenterology 2007; 428: 923-32.
  20. Conroy R.M, Pyorala K, Fitzgerald A.P et al. SCORE project group. Estimation of ten - year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
  21. Jordan K.M, Arden N.K, Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.
  22. Hochberg M.C, Altman R.D, April K.T et al. American College of Rheumatology 2012 recommendation for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465-74 [review].
  23. Zhang W, Moskowitz R.W, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Ostearthr Cartilage 2007; 15: 981-1000.
  24. Zhang W, Moskowitz R.W, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence - based expert consensus guidelines. Ostearthr Cartilage 2008; 16: 137-62.
  25. Zhang W, Nuki G, Moskowitz R.W et al. OARSI recommendation for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage 2010; 18: 476-99.
  26. Bannuri R.R, Dasi U.R, Mc Alindon T.E. Reassessing the role of acetaminophen in osteoarthritis: a systematic review and meta - analysis. Osteoarthr Cartilage 2010; 18 (Suppl. 2): S250.
  27. Herrero-Beaumont G, Ivrora J.A, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double - blind, placebo - controlled study using acetaminophen as a side comparator. Arthr Rheum 2007; 56: 555-67.
  28. Muller-Fabender H, Bach G.L, Haase W et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2 (3): 61-9.
  29. Алексеева Л.И., Беневоленская Л.И., Насонов Е.Л. и др. Структум (хондроитин - сульфат) - новое средство для лечения остеоартроза. Терапевт. арх. 1999; 5: 51-3.
  30. Yaron I, Shirasi R, Judovich R, Yaron M. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000; 59 (Suppl. 1): 265.
  31. Mazieres B, Combe B, Phan Van V et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheum 2001; 28: 173-81.
  32. Reginster J.Y, Deroisy R, Rovati I.C et al. Long - term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo - controlled clinical trial. Lancet 2001; 367: 251-6.
  33. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo - controlled, double - blind study. Arch Intern Med 2002; 162: 2113-23
  34. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta - analysis. Br Med J 2010; 341: c4675.
  35. Mc Alindon T.E, La Valley M.P, Gulin J.P, Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta - analysis. JAMA 2000; 283: 1469-75.
  36. Leeb B.F, Schweitzer H, Montag K, Smolen J.S. A meta - analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-11.
  37. Richy F, Bruyere O, Ethgen O. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta - analysis. Arch Intern Med 2003; 163: 1514-22.
  38. Pelletier J.P, Raunauld J.P, Beaulieu A et al. In a two - year double - blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients. Arthr Rheum 2015, 67 (S10): Abstract Supplement 2015 ACR/ARHP Annual Meeting November 2015: Abstr. 950.
  39. Lippielo L, Woodword J, Karpman D et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
  40. Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618-22.
  41. Lippiello L. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000; 381: 229-40.
  42. Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med 2007; 4 (2): 219-24.
  43. Clegg D.O, Reda D.J, Harris C.L et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795-808.
  44. Алексеева Л.И., Беневоленская Л.И., Зайцева Е.М. Эффективность препарата Терафлекс у больных с остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ. 2005; 13 (8): 525-7.
  45. Лила А.М., Мазуров В.И., Шидловская О.В., Шостак М.С. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618-22.
  46. Маличенко С.Б., Колесова И.Р. Изучение клинической эффективности и переносимости препарата Терафлекс (глюкозамин гидрохлорид - 500 мг и натрий хондроитин сульфата - 400 мг) при суставном синдроме у женщин в физиологической и хирургической менопаузе (отчет). М., 2005.
  47. Алексеева Л.И. Результаты открытого сравнительного рандомизированного исследования эффективности и безопасности 2-х схем лечения препаратом Терафлекс у пациентов с остеоартрозом коленного сустава. Клиническое исследование. РМЖ. 2008; 16 (5): 316-9.
  48. Hochberg M.C, Martel-Pelletier J, Monfort J et.al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double - blind, non - inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75: 37-44.
  49. Castellsague J et al. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf 2012; 35 (12): 1127-46.
  50. Fournier J.P et al. Non - steroidal anti - inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population - based cohort study Eur J Clin Pharmacol 2012; 68: 1533-40. doi: 10.1007/s00228-012-1283-9
  51. Mc Gettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098. doi: 10.1371/journal.pmed.1001098
  52. Tallarida RJ, Cowan A, Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 2003; 307: 699-704.
  53. Алексеева Л.И. Открытое рандомизированное сравнительное исследование эффективности и безопасности препарата Терафлекс Адванс по сравнению с препаратами Терафлекс и ибупрофен у пациентов с остеоартрозом коленных суставов. Научный отчет. 2008.
  54. Поворознюк В.В. Эффективность препарата Терафлекс Адванс в лечении болевого синдрома при остеоартрозе коленных суставов. Здоров'я Украины. 2007; 1-3.
  55. Орлова С.П., Любарский Е.А., Термалаян Н.В., Хозин А.А. Отчет о применении препарата Терафлекс в лечении вертеброгенных болей. 1 неврологическое отделение МЛПУЗ «Городская больница №4». Р.-н/Д.
  56. Fairbank J, Mbaot J.C, Davies J.B, O`Brien J.P. The Oswestry Low Back Pain Disability Questionnaire. Physiotherapy 1980; 66: 271-4.
  57. Fransen M, Agaliotis M, Nairin L et al. Glucosamine and chondroitin for knee osteoarthritis: a double - blind randomised placebo - controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014; 73: 1-8. doi: 10.1136/annrheumdis-2013-203954
  58. Martin-Pelletier J, Roubille C, Abram F et al. First - line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547-56.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies